All In Biotech

Drug Trial Radar · NCT05817812

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

A Phase 3b Open-label Study Evaluating Physical Activity and Joint Health in Previously Treated Patients ≥12 Years With Severe Haemophilia A Treated With Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (Efanesoctocog Alfa) for 24 Months

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

93

Actual

Start

Jul 31, 2023

Primary completion

Jun 2, 2026

Study completion Jun 2, 2026

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis. After a run-in period of 30-45 days, patients will receive efanesoctocog alfa prophylaxis, 50 IU/kg once-weekly for 24 months (additional preventive dose not permitted). An activity tracker and an electronic patient diary will be used to collect data on physical activity, bleeds, factor dosing, pain, and injuries from screening throughout the study. The primary objective is to describe changes in physical activities over 24 months on efanesoctocog alfa prophylaxis, with a primary endpoint of change from baseline in International Physical Activity Questionnaire (IPAQ) at month 24. Secondary objectives include relationship between physical activity and other variables (bleeds, joint status, pain, injuries, and quality of life); changes in joint status as assessed by HEAD-US, HJHS and MRI; occurrence of bleeds, injuries, pain. Safety and tolerability of efanesoctocog alfa will also be evaluated.

Conditions

  • Hemophilia A, Severe

Interventions

  • Efanesoctocog alfaDrug

    Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in International Physical Activity Questionnaire (IPAQ) scoringTime frame: Baseline and month 24

Locations

30 sites in 14 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Vienna, Austria

  • Investigational Site

    Zagreb, Croatia

  • Investigational Site

    Brno, Czechia

  • Investigational Site

    Prague, Czechia

  • Investigational Site

    Bordeaux, France

  • Investigational Site

    Le Kremlin-Bicêtre, France

  • Investigational Site

    Marseille, France

  • Investigational Site

    Strasbourg, France

  • Investigational Site

    Berlin, Germany

  • Investigational Site

    Frankfurt, Germany

  • Investigational Site

    Giessen, Germany

  • Investigational Site

    Hamburg, Germany

  • Investigational Site

    Athens, Greece

  • Investigational Site

    Dublin, Ireland

  • Investigational Site

    Catanzaro, Italy

  • Investigational Site

    Florence, Italy

  • Investigational Site

    Naples, Italy

  • Investigational Site

    Parma, Italy

  • Investigational Site

    Rome, Italy

  • Investigational Site

    Utrecht, Netherlands

  • Investigational Site

    Oslo, Norway

  • Investigational Site

    Ljubljana, Slovenia

  • Investigational Site

    Barcelona, Spain

  • Investigational Site

    Madrid, Spain

  • Investigational Site

    Oviedo, Spain

  • Investigational Site

    Lund, Sweden

  • Investigational Site

    Solna, Sweden

  • Investigational Site

    Canterbury, United Kingdom

  • Investigational Site

    Newcastle upon Tyne, United Kingdom

  • Investigational Site

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.